34 ms·
Which is good numbers in the cancer treatment arena. >> “We look forward to continued constructive conversations with the FDA as we move forward in our plan to
by adamredwoods 2y ago
Which is good numbers in the cancer treatment arena.
>> “We look forward to continued constructive conversations with the FDA as we move forward in our plan to initiate a phase 3 trial in previously treated HNSCC mid-2024 and prepare for a potential phase 3 trial evaluating the combination of petosemtamab and pembrolizumab [Keytruda] in previously untreated patients."
I understand the caution, but I firmly believe oncologists need to get more aggressive with multi-line treatments.
- vibrio 2y agoI’m not sure I agree that conservatism treatment by oncologists is holding back cancer cure. Maybe in some cases but in others… eg multi-drug regimes like FOLFIRINOX, where cancer patients routinely choose hospice over treatment because of its toxicity and meager benefit. Or even more cutting edge drugs like ENHERTU, which has shown striking benefits for some, but something like 15% of patients have to be pulled off treatment due to intolerable toxicities, and twice that amount have serious adverse events and occasional patients die (“grade 5 to x”) I agree there is much work to do in cancer, and oncologist behavior is included in that. Simply getting more aggressive may help some but isn’t necessarily a magic bullet and has risks. (please pardon my emotional reaction to this) .
- sam537 2y agoThe problem here is the potential toxicity of this combination. In lung cancer for example, the combination of anti-EGFR therapy + pembrolizumab led to deadly pneumonitis (lung inflammation). We want to cure more patients, but we don't want to kill them before their cancer.